Louisiana pharmacist to Congress: Independents need to stay in the DME business
ALEXANDRIA, Va. — Louisiana pharmacist Randy Mire testified before Congress Tuesday that efforts to combat the diabetes epidemic in his home state and elsewhere would be significantly undermined if independent community pharmacies like his are forced to stop offering diabetes testing supplies as a result of Medicare’s competitive bidding program for durable medical equipment, according to a National Community Pharmacists Association release.
Mire appeared on behalf of NCPA before the U.S. House Small Business Subcommittee on Healthcare and Technology.
“My pharmacy is one of the very few pharmacies still in the area that provides these essential DME supplies to patients,” testified Mire, owner of Gem Drugs, located in Reserve and Gramercy, La. “To me, these patients are more than just a prescription. I provide DME supplies in order to make certain that the beneficiaries have access to the supplies that they need. If I were to decide not to offer these DME supplies because the burden of offering such supplies has become too high and the cost too much, then these beneficiaries would have nowhere else to turn to receive the face-to-face consultations and quality supplies that I provide to them and that they deserve.”
The Bayou State has among the highest diabetes rates in the nation, he noted, and his patients have complained that mail-order deliveries lack adequate patient consultations and are unreliable — a fact driven home by the recent impact of Hurricane Isaac on his community.
Mire urged lawmakers to support H.R. 1936, The Medicare Access to Diabetes Supplies Act. The bipartisan legislation would allow small pharmacies — defined as 10 locations or fewer — to continue to furnish patients with diabetes testing supplies and personalized counseling on their proper use, as competitive bidding is implemented.
NCPA noted that a recently conducted survey of more than 400 community pharmacists found:
About 92% of independent community pharmacies would be forced to leave the Medicare diabetes test supply program if presented with a sharp reduction in payments;
More than 50% of community pharmacies said that the average Medicare diabetic patient comes to their pharmacy at least three times per month for diabetic supplies and/or counseling;
83% of community pharmacists said that the impact on patients if they had to obtain diabetes supplies from mail order would be significant; and
45% of community pharmacies deliver diabetes testing supplies to assisted living facilities. CMS’ current competitive bidding proposal would prohibit these pharmacies from doing so.
In addition to Mire’s testimony (available in its entirety here), NCPA submitted written comments to the subcommittee (available here).
Interested in this topic? Sign up for our weekly Collaborative Care e-newsletter.